Congress Materials – Congress of Clinical Dermatology (CCD 2025)
2025 Congress of Clinical Dermatology | May 29-Jun 1 | Amelia Island, FL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial
Robert Bissonnette, Jennifer Soung, Adelaide Hebert, Andrew E. Pink, Andreas Pinter, Yuling Shi, Megan Miller, Joseph Cafone, Jing Zhi (Gigi) Jiang, Cynthia DeKlotz, Mark G. Lebwohl
VISIBLE Cohort B: Guselkumab Demonstrated Scalp Clearance and Improved Health-Related Quality of Life Through Week 48 in Participants With Moderate-to-Severe Scalp Psoriasis Across All Skin Tones
A. McMichael, T. Bhutani, S. Smith, T. Alkousakis, O. Choi, D. Chan, T. Ma, R. Radusky, J. Yeung, G. Han, S.C. Taylor
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.